Skip to main content
The Peptide Clinic

Growth hormone peptide research

Everything on this page describes laboratory research. Compounds named here are supplied for in-vitro and analytical work by verified researchers only. None is a registered medicine in South Africa, none is approved for human or veterinary use, and nothing on this page is guidance for use in a person.

Apply for verified access

This area covers peptides studied for their interaction with the somatotropic axis: the signalling that governs release of growth hormone from the pituitary, and the measurable consequences downstream of it. Everything described here is a secretagogue, meaning a compound studied for its action on the body's own release machinery rather than one that supplies the hormone itself. That distinction is the reason this class is studied separately, and it is worth holding on to when reading the literature.

CompoundsCJC-1295, Ipamorelin, Tesamorelin
The Clinic box with its silver THE Clinic wordmarkResearch peptide cartridge

What the research measures

Release dynamics

Amplitude and frequency of pituitary release in animal models and in cell culture. The axis operates in pulses rather than at a steady level, and the pattern is thought to carry as much information as the total.

Receptor selectivity

Which receptors a compound engages and which it leaves alone. This is the main axis on which the class is compared, because engagement at related receptors is what drives the confounding effects reported in earlier work.

Downstream markers

Insulin-like growth factor concentrations and the signalling that follows them, commonly used as the readout because they integrate a pulsatile signal into something a single measurement can capture.

Clearance

How long a compound persists before it is cleared. This differs by more than an order of magnitude across the class and is the largest practical difference between its members.

Compounds studied in this area

CJC-1295

Modified growth hormone releasing hormone (1-29)

A synthetic analogue of the first twenty-nine amino acids of growth hormone releasing hormone, which is the shortest fragment that retains activity. Two versions appear in the literature: one carrying a drug affinity complex that binds albumin in circulation, and one without it. That binding is the whole difference between them, and it changes clearance by a wide margin.

Research examines release dynamics at the pituitary, how long the signal persists, and downstream insulin-like growth factor concentrations in animal models. The albumin-binding version is the more studied of the two, precisely because its extended presence in circulation is what makes the pulsatility question tractable at all.

Ipamorelin

Aib-His-D-2-Nal-D-Phe-Lys-NH2

A synthetic pentapeptide acting at the growth hormone secretagogue receptor, which is a different receptor from the one the releasing-hormone analogues engage. By mechanism it is a ghrelin mimetic, though a notably selective one.

Published work centres on receptor selectivity relative to earlier compounds of the same class, which also engaged adrenocorticotropic and prolactin pathways alongside the intended one. That selectivity is why it is the reference compound through much of this literature.

Tesamorelin

Trans-3-hexenoyl growth hormone releasing factor (1-44)

A stabilised analogue of the full forty-four amino acid growth hormone releasing factor, modified at the amino end to resist the enzyme that ordinarily degrades it. It is the longest of the three described here.

It carries the most developed clinical evidence base in this class, though almost all of it comes from work on visceral adipose tissue in one specific patient population. That makes the literature unusually well controlled and also unusually narrow, and reading across from that population to any other is exactly the step the evidence does not support.

Laboratory handling and storage

Lyophilised peptide is the stable form. It is normally held below freezing and protected from light.

Reconstituted material has a substantially shorter working life than the lyophilised form, and that window is the usual limiting factor in planning an experiment.

Albumin-binding variants behave differently in serum-containing media than in serum-free conditions, which is a recognised source of irreproducibility in this class and belongs in any written method.

Repeated freeze and thaw cycles degrade peptide integrity, so single-use aliquots are the standard practice.

Handling, reconstitution and disposal are laboratory procedures and should follow the receiving facility's own written procedures and local regulations.